Real World Evidence

The potential of personal health records to bridge the gap between research and care.

Webinar Date/Time: Thursday, May 9th, 2024 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

Webinar Date/Time: Tue, Mar 26, 2024 11:00 AM EDT

Webinar Date/Time: Wed, Mar 27, 2024 11:00 AM EDT

Study highlights the potential of a comprehensive, multistakeholder-driven data analysis pipeline that addresses individual data sharing, core data set sharing, and federated model sharing.

Webinar Date/Time: Tue, Oct 17, 2023 11:00 AM EDT

Webinar Date/Time: Thursday, May 25th, 2023 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

Panel discusses what real-world evidence—and related patient-reporting technology—need to achieve to better influence payer decision-making.

Webinar Date/Time: Thu, May 4, 2023 10:00 AM EDT

Webinar Date/Time: Tue, Mar 28, 2023 11:00 AM EDT

Webinar Date/Time: Thu, Mar 16, 2023 11:00 AM EDT

Craig Coleman, PharmD, Professor at the University of Connecticut, and the Observational Study in Cancer-Associated Thrombosis for Rivaroxaban (OSCAR) study's principal investigator discusses the ins and outs of the study.

Webinar Date/Time: Mon, Feb 13, 2023 10:00 AM EST

Webinar Date/Time: Tuesday, December 13, 2022 at 10am ET | 3pm GMT | 4pm CET

Survey among readers evaluates the trajectory of RWD and how it can be more widely adopted.

Addressing sources of tension on differentiating types of data.

By integrating real-world data more deeply into the process of clinical research, life sciences stakeholders can open up new possibilities for therapeutic development and the evidence-based treatment of hematologic cancers.

RWE can augment, extend, or enrich the findings from clinical trials to provide valuable evidence to support the development programs for product approvals.

C.K. Wang, MD, senior medical director at COTA Inc., discusses the impact of RWD and RWE in clinical oncology.

A look at the scope of the agency’s draft framework for evaluating the use of RWE to support new drug approvals and the implications for sponsors.

With outcomes from “real life” a critical compliment to clinical trial data, the importance of involving an epidemiologist at study inception is explored.

Karen Hill and Heather Fitzpatrick Medlin discuss the recent advancements and challenges in cardiovascular and metabolic studies, as well as strategies to address current obstacles and advance the industry further.

Study examines the growing integration of real-world data and evidence and the remaining roadblocks to adoption.